FDA clears ResMed noninvasive COPD treatment device

28 April 2013 (Last Updated April 28th, 2013 18:30)

The US Food and Drug Administration has approved ResMed's home variable positive airway pressure (VPAP) device for minimising hospital readmissions.

The US Food and Drug Administration has approved ResMed's home variable positive airway pressure (VPAP) device for minimising hospital readmissions.

Designed for the treatment of chronic obstructive pulmonary disease (COPD), the FDA clearance allows the company to make bilevel therapy more accessible through Medicare's Respiratory Assist Device qualifying guidelines.

The device, when wirelessly connected to ResMed's cloud-based EasyCare online monitoring system, allows physicians, hospitals and homecare partners to monitor patient use and patient respiratory health on a daily basis.

"Designed for the treatment of chronic obstructive pulmonary disease (COPD), the FDA clearance allows the company to make bilevel therapy more accessible through Medicare's Respiratory Assist Device qualifying guidelines."

Built on the ResMed S9 series platform, the product customises the breath delivered to the patient with a rapid inhalation phase and allows an extended exhalation.

The device also creates a comfortable patient experience and increases the likelihood of patients to continue the therapy, when combimed with the companion H5i heated humidification device, accoding to the company.

In addition, ResMed has created a special ClimateLine tubing between the humidifier and mask that has an oxygen line port next to the VPAP COPD device.

ResMed respiratory care business unit president Geoff Neilson said the device gives patients a no-compromise solution, with bilevel therapy and humidification without condensation.

"ResMed takes advantage of each building block for a positive patient experience, from superior comfort to an attractive and easy-to-use device," Neilson said.